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Abstract
Background: Anaplastic thyroid cancer (ATC) is a rare, lethal disease associated with a median survival of 6
months despite the best multidisciplinary care. Surgical resection is not curative in ATC patients, being often a
palliative procedure. Multidisciplinary care may include surgery, loco-regional radiotherapy, and systemic therapy.
Besides conventional chemotherapy, multi kinase-targeted inhibitors are emerging as novel therapeutic tools. The
numerous molecular alteration detected in ATC are targets for these inhibitors. The aim of this review is to
determine the prevalence of the major genetic alterations occurring in ATC and place the results in the context of
the emerging kinase-targeted therapies.
Methods: The study is based on published PubMed studies addressing the prevalence of BRAF, RAS, PTEN, PI3KCA
and TP53 mutations and RET rearrangements in ATC.
Results: 21 articles dealing with 652 genetic analyses of the selected genes were used. The overall prevalence
determined were the following: RET/PTC, 4%; BRAF, 23%; RAS, 60%; PTEN, 16%; PI3KCA, 24%; TP53, 48%. Genetic
alterations are sometimes overlapping.
Conclusions: Mutations of BRAF, PTEN and PI3KCA genes are common in ATC, with RAS and TP53 being the most
frequent. Given ATC genetic complexity, effective therapies may benefit from individualized therapeutic regimens
in a multidisciplinary approach.
Introduction
Thyroid cancer is the most prevalent endocrine malig-
nancy accounting for 1% of cancers worldwide. More
than 95% of thyroid cancer are well differentiated
tumors that respond to surgery followed by radioactive
iodine (RAI) therapy and thyroid hormone suppression.
Although disease recurrence occurs in approximately
30% of cases, nowadays thyroid cancers have a very
favorable outcome. The clinical appearance of thyroid
cancer is that of a nodules, some time representing a
challenging diagnostic dilemma with thyroid or unusual
extrathyroidal masses [1,2]. The use of effective diagnostic
tools such as ultrasound (US) and fine-needle cytology
(FNC) [3-5] has increased the detection of small and well
differentiated tumors in their early stages. Moreover, the
application of molecular techniques to FNC has dramati-
cally increased its sensitivity [3,4,6-9]. An effective FNC
diagnosis avoids useless diagnostic surgery or provides
indications for the proper surgical treatment, when needed
[10,11]. Poorly differentiated subtypes, including anaplastic
thyroid cancer (ATC), are resistant to RAI and conven-
tional chemotherapy. ATC accounts for about 1% of thyr-
oid cancer and is typical of old age. When feasible, surgery
must aim at a radical intent; however, surgical resection
is not curative in ATC patients, being often a palliative
procedure [10,11]. Therefore, an early and accurate diag-
nosis is mandatory in case of ATC which does not require
surgical treatment, and even more in elderly patients, for
whom surgery is generally more burdensome, complex
and expensive than younger patients [10,11]. Standard
chemotherapies have systemic toxicities and limited
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efficacy in the case of ATC as well as of other more com-
mon solid tumors [12-14]. Alternative strategies such as
immunotherapy are under investigation, but still far from
clinical practice [15]. At present, genetic-based targeted
therapy is the most promising curative strategy. Hallmarks
of all cancers are self-sufficiency in growth signals and eva-
sion of programmed cell death. Tyrosine kinase receptors/
RAS/RAF/MAPK and RAS/PI3K/Akt/mTOR are the
major signaling pathways involved in cell proliferation,
protein synthesis and cell survival. Thyroid cancer is char-
acterized by several genetic alterations along these two
pathways, including rearrangements of the RET (rear-
ranged during transfection; RET/PTC) tyrosine receptor
kinase, activating point mutations in the BRAF serine/
threonine kinase, in the RAS proto-oncogenes, in the cata-
lytic subunit of the phosphatidyl-inositol 3-Kinase
(PI3KCA), or inactivating mutations in the tumor suppres-
sors phosphatase and tensin homolog (PTEN) and TP53
(Table 1). ATC is the product of the accumulation of
genetic alterations due to genetic instability and external
factors such as food or environmental factors, including
ionizing radiations and oxidative stress. Oxidative stress
has been implicated in the mechanism of cancer, diabetes,
cardiovascular and other diseases [16,17]. Oxidant mole-
cules are generated by stress agents such chemicals, drugs,
pollutants, and high-caloric diets [18]. Conversely, there is
no hint of a remodeling of the Ca2+ toolkit, that has been
observed in other malignancies, including renal cellular
carcinoma [19-21], and prostate cancer [22], and has been
put forward as alternative target for selective molecular
therapies [14]. The last decade has seen advances in the
understanding of the molecular basis of thyroid cancer,
leading to the application of new pharmacological treat-
ments with inhibitors of kinases [23-25]. These drugs are
multi-target agents with inhibitory activity of receptors
involved in the angiogenesis or inhibitors of kinases
involved in thyroid cancer development. The BRAF inhibi-
tor vemurafenib (PLX4032) improves survival among
patients with metastatic melanoma, and suppresses growth
of BRAF-mutated human ATC in a mouse model [26].
The beneficial effect of BRAF inhibition in ATC with acti-
vating BRAF mutations has been recently reported [27].
Other pharmacological compounds inhibit RET and RET/
PTC (sorafenib, sunitinib, vandetanib) or the mammalian
target of rapamycin (mTOR), a component of the PI3K/
Akt signaling pathway (everolimus). Hence, the knowledge
of the tumor mutation status is needed for optimizing and
tailoring the treatment with kinase inhibitors. The intent
of this systematic review is to determine the prevalence of
the major genetic alterations occurring in ATC.
Materials and methods
A meta-analysis was performed by searching the MED-
LINE database (National Library of Medicine, Bethesda,
MD) using the terms “BRAF”, “RAS”, “PTEN”, “PI3KCA”,
“TP53”, “RET/PTC” or ‘’BRAF,’’ associated with the terms
‘’anaplastic thyroid cancer” or “undifferentiated thyroid
cancer’’. Studies were included only when the sample
was ≥ 4. Studies were selected on the basis of the detection
of molecular alterations by genetic analysis. Studies based
only on molecular detection by immunohistochemistry
were excluded. Only data about different genes were
included from studies by the same authors. Studies on
poorly differentiated thyroid cancers and well differen-
tiated thyroid cancers were also excluded.
Results
The literature search strategy retrieved 104 articles from
PubMeD. Twenty-one studies met the inclusion criteria
and were considered for further analysis. These studies
were published between 1993 and 2010, and included
652 cases of ATC. All studies were retrospective, using
stored formalin-fixed paraffin-embedded samples or
frozen surgical specimens. The method used for deter-
mining the presence of single point mutations was
direct sequencing of DNA after polymerase-chain reac-
tion (PCR) amplification, PCR and fluorescence melting
curve analysis and DNA-mutant allele-specific amplifi-
cation (DNA-MASA). The methods used to determine
RET rearrangements were PCR alone followed by direct
sequencing or PCR followed by internal probe binding
(Southern blot on PCR products). BRAFV600E was the
only BRAF mutation considered by the 7 studies analyzed.
The mutation ranged 0%-50% in 21 out of 89 tumors
(Table 2). The mean prevalence was 23%. Mutations in the
three RAS isoforms ranged 8%-60% in 33 out of 162 ATCs
(mean 60%). Not all the three major RET rearrangements
were considered in all studies. Tumors were tested for the
presence of RET/PTC-1 and -3 in two studies and RET/
PTC-1, -2, and -3 in one study. Rearrangements were
rare, being detected in 4% of ATCs, in the range 0%-6%
in 3 out of 81 tumors. Inactivating mutations of PTEN
were detected in 16% of 107 ATCs, while activating
mutations of PI3KCA in 23% of 70 ATCs in the range
12%-58% (Table 3). Inactivating mutations of TP53 were
identified in 48% of 25 tumors, in the range 10%-86%.
Table 1 Gene mutations in ATC
Gene Mutation Signaling involvement
RET Recombination MAPK activation
BRAF Single point mutation MAPK activation
H-, N-, K-
RAS
Single point mutation MAPK, PI3K/Akt/mTOR
activation
PTEN Single point mutation/
deletion
PI3K/Akt/mTOR inactivation
PI3KCA Single point mutation PI3K/Akt/mTO activation
TP53 Single point mutation P53 pathway inactivation
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Discussion
The prognosis of differentiated thyroidal tumors is gener-
ally favorable mainly because there are different and
effective tools in the early diagnosis and treatment of
these tumors [28]. In fact, the use of US and FNC in the
diagnosis of thyroid nodules usually leads to an early and
accurate diagnosis of small and differentiated tumors, as
well as less frequent thyroidal neoplasms [3,5,6]. In parti-
cular FNC, coupled with immunocytochemistry (ICC),
flow cytometry (FC) and molecular techniques
[3-6,29-31] has dramatically enhanced the sensitivity and
the accuracy of preoperative diagnosis of thyroidal
nodules [3,5,29]. The bad prognosis of advanced thyroid
carcinoma, prompted researchers to evaluate the efficacy
of new pharmaceutical compounds with enzymatic inhi-
bitory properties (Table 4). The prevalence of RET/PTC
rearrangements in ATC was much lower than in papillary
thyroid cancer reported in most of the studies (4% vs.
36%) [25,32]. Noteworthy, benign thyroid nodules exhi-
biting RET/PTC rearrangements do not evolve in cancer
[33,34]. This data suggest that this oncogene has a minor
role in the progression from well-differentiated to undif-
ferentiated thyroid cancer. It also indicate that tyrosine
kinase inhibitors such as sorafenib, sunitinib, and vande-
tanib have little chance to function through the inhibition
of this oncogene in ATC. The encouraging results
obtained by these drugs in non RAI-responsive differen-
tiated thyroid carcinomas in some clinical trials where
the RET rearrangement was not evaluated, were more
likely due to the effects on neo-angiogenesis [35]. The
high prevalence of BRAFV600E mutation in ATC supports
the hypothesis that many ATCs actually represent a
progressive malignant degeneration of BRAF-mutated,
well-differentiated thyroid carcinomas [36]. This gene is
a pivotal component of the MAPK pathway and reduces
the activity of p21kip1 in thyroid tumors, stimulating
the cell cycle machinery [37]. Vemurafenib (PLX4032),
a BRAF selective kinase inhibitor and sorafenib, a multi-
target inhibitor, find application in selected BRAF-
mutation positive melanomas [38]. Although clinical stu-
dies of BRAF inhibitors in advanced non RAI-responsive
differentiated thyroid carcinomas have shown encoura-
ging results with frequent early responses, in a relevant
fraction of patients this effect was of limited duration,
with frequent relapse or no response. In addition, intra-
tumoral heterogeneity with respect to BRAF mutation
makes the evaluation of these clinical trials even more














Overall BRAFV600E 21/89 23










RET/PTC 0/14 0 [63]
3/51 6 [44]
0/17 0 [64]
Overall RET/PTC 3/81 4
Table 3 Prevalence of mutations not in the MAPK
pathway in ATC
Mutation Positive/ total cases Prevalence (%) Reference
PTEN 8/48 17 [44]
8/50 16 [61]
1/9 10 [65]
Overall PTEN 17/107 16




Overall PI3KCA 45/188 24
TP53 1/11 10 [67]
5/7 71 [19]
6/7 86 [68]
Overall TP53 12/25 48
Table 4 Major pharmaceutical compounds in clinical






Axitinib + - + -
Cabozantinib +/- - - -
Lenvatinib + - + -
Motesanib + - + -
Pazopanib + - + -
Sorafenib + + + + -
Sunitinib + + - + -
Vandetanib + + - - -
Vemurafenib - - + - -
Everolimus - - - - +
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complex [39,40]. Poor results were obtained with sorafenib
in ATC, although positive results reported with vemura-
fenib in one ATC with BRAFV600E mutation are worthy
to be mentioned [27,35]. A relevant obstacle to the effi-
cacy of treatments based on the inhibition of BRAFV600E
is the presence of activating mutations of RAS. This
proto-oncogene is a small GTP binding protein located
upstream RAF in the MAPK cascade. Activating muta-
tions of this protein reactivate the MAPK pathway, mak-
ing BRAFV600E inhibition inefficient [41]. The high
prevalence of RAS activating mutations in ATC (60%)
makes the inhibition of the MAPK pathway by kinase
inhibitors a strategy whose success is unlikely. Moreover,
papillary thyroid carcinoma and ATC exhibit concomi-
tant BRAFV600E and RAS mutations, although a rare
occurrence [42-44]. In light of these considerations, the
pharmacological inhibition of the MAPK pathway looks
less promising than the inhibition of the PI3K/Akt/
mTOR pathway. This pathway is constitutively activated
by inactivating mutations of PTEN and by activating
mutations of PI3KCA. Both mutations are frequent in
ATC (10% and 24% respectively). Ongoing studies in
cells, both in culture and in vivo, are investigating the
anticancer effect of the novel allosteric Akt inhibitor,
MK2206, in combination with several anticancer agents
[45]. This agent selectively inhibits thyroid cancer cells
harboring mutations that can activate the PI3K/Akt path-
way [46,47]. An appealing feature of Akt/mTOR inhibi-
tors is the possibility of treating advanced thyroid cancer
also when resistance to single targeted therapy is con-
ferred by multiple genetic alterations. Most of the kinase
inhibitors currently under investigation are multitargeted
inhibitors, with a beneficial double effect impairing the
viability of tumor cells and tumor vascularization
[13,14,20,48]. The TP53 tumor suppressor gene increases
the cyclin kinase inhibitor p21kip1, promoting cell cycle
arrest at G1/S. Its inactivation by a mutation impairs the
correct modulation of cell proliferation and apoptosis.
This gene is mutated in 48% of ATC. The loss of the
TP53 mediated control of the apoptotic machinery is
probably the most difficult obstacle to overcome for a
pharmacological agent to be active in ATC. Beneficial
effects in ATC cell lines have been observed with an
adenovirus TP53-regulated Cre/loxP system and with a
E1B gene-defective adenovirus (ONYX-015) in TP53
mutant cells [49,50].
Conclusions
ATC is characterized by genomic instability that leads to
mutations in RET, BRAF, RAS, PTEN, PIK3CA and
TP53 genes. The survival of ATC patients has changed
little in the past 50 years, despite the introduction of
new therapeutic tools. Given the complexity of the
genomic alterations of ATC, therapy results may benefit
from individualized therapeutic regimen that maximally
inhibits major pathways. In the future, these therapies
may be successful with a multidisciplinary approach.
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